ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 233 filers reported holding ROYALTY PHARMA PLC in Q3 2021. The put-call ratio across all filers is 0.36 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $341,367 | -95.2% | 12,578 | -94.6% | 0.00% | -90.0% |
| Q2 2023 | $7,126,116 | -13.6% | 231,819 | +1.3% | 0.01% | -16.7% |
| Q1 2023 | $8,247,086 | -9.0% | 228,895 | -0.1% | 0.01% | -14.3% |
| Q4 2022 | $9,058,537 | +5.0% | 229,214 | +6.8% | 0.01% | 0.0% |
| Q3 2022 | $8,625,000 | -11.3% | 214,661 | -7.1% | 0.01% | -6.7% |
| Q2 2022 | $9,721,000 | +27.9% | 230,954 | +18.5% | 0.02% | +50.0% |
| Q1 2022 | $7,599,000 | +14.0% | 194,849 | +16.4% | 0.01% | +11.1% |
| Q4 2021 | $6,668,000 | +28.6% | 167,332 | +16.6% | 0.01% | +12.5% |
| Q3 2021 | $5,187,000 | -12.7% | 143,530 | -1.0% | 0.01% | +14.3% |
| Q2 2021 | $5,941,000 | -4.1% | 144,928 | +2.0% | 0.01% | -12.5% |
| Q1 2021 | $6,196,000 | -49.4% | 142,034 | -41.9% | 0.01% | -11.1% |
| Q4 2020 | $12,240,000 | +132.1% | 244,564 | +97.0% | 0.01% | +12.5% |
| Q3 2020 | $5,273,000 | +11.3% | 124,169 | +27.2% | 0.01% | -11.1% |
| Q2 2020 | $4,739,000 | – | 97,606 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $244,378,000 | 79.54% |
| Vantage Consulting Group Inc | 7,862,542 | $284,152,000 | 60.85% |
| Memorial Sloan Kettering Cancer Center | 2,680,644 | $96,878,000 | 60.36% |
| Indie Asset Partners, LLC | 701,323 | $25,346,000 | 20.53% |
| HARVARD MANAGEMENT CO INC | 7,142,856 | $258,143,000 | 15.13% |
| Bleichroeder LP | 1,115,980 | $40,332,000 | 6.55% |
| Overbrook Management Corp | 785,132 | $28,375,000 | 6.16% |
| Geo Capital Gestora de Recursos Ltd | 194,305 | $7,022,000 | 3.21% |
| Brown University | 621,759 | $22,470,000 | 3.05% |
| Graypoint LLC | 610,584 | $22,067,000 | 2.71% |